Literature DB >> 29342456

Correlation between Resection Margin and Disease Recurrence with a Restricted Cubic Spline Model in Patients with Resected Hepatocellular Carcinoma.

Woohyung Lee1,2, Ho-Seong Han1, Soyeon Ahn3, Yoo-Seok Yoon1, Jai Young Cho1, YoungRok Choi1.   

Abstract

BACKGROUND: The relationship between resection margin (RM) and recurrence of resected hepatocellular carcinoma (HCC) is unclear.
METHODS: We reviewed clinical data for 419 patients with HCC. The oncologic outcomes were compared between 2 groups of patients classified according to the inflexion point of the restricted cubic spline plot.
RESULTS: The patients were divided according to an RM of <1 cm (n = 233; narrow RM group) or ≥1 cm (n = 186; wide RM group). The 5-year recurrence-free survival (RFS) rate was lower (34.8 vs. 43.8%, p = 0.042) and recurrence near the resection site was more frequent (4.7 vs. 0%, p = 0.010) in the narrow RM group. Patients with multiple lesions, or prior transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) were excluded from subgroup analyses. In patients with a 2-5 cm HCC, the 5-year RFS was greater in the wide RM group (54.4 vs. 32.5%, p = 0.036). Narrow RM (hazard ratio 1.750, 95% CI 1.029-2.976, p = 0.039) was independently associated with disease recurrence.
CONCLUSION: In patients with a single 2-5 cm HCC without prior TACE/RFA, an RM of ≥1 cm was associated with lower risk of recurrence after liver resection.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Hepatocellular carcinoma; Recurrence; Resection margin; Restricted cubic spline

Mesh:

Year:  2018        PMID: 29342456     DOI: 10.1159/000485805

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  7 in total

1.  Validation of the prognostic performance in various nodal staging systems for gallbladder cancer: results of a multicenter study.

Authors:  Woohyung Lee; Chi-Young Jeong; Young Hoon Kim; Young Hoon Roh; Myung Hee Yoon; Hyung Il Seo; Jeong-Ik Park; Bo-Hyun Jung; Dong Hoon Shin; Young Il Choi; Je Ho Ryu; Kwang Ho Yang; Chang Soo Choi; Yo-Han Park; Yang Won Nah; Soon-Chan Hong
Journal:  Langenbecks Arch Surg       Date:  2019-08-14       Impact factor: 3.445

2.  Impact on Oncological Outcomes and Intent-to-Treat Survival of Resection Margin for Transplantable Hepatocellular Carcinoma in All-Comers and in Patients with Cirrhosis: A Multicenter Study.

Authors:  Chetana Lim; Claire Goumard; Margarida Casellas-Robert; Santiago Lopez-Ben; Laura Lladó; Juli Busquets; Chady Salloum; Maria Teresa Albiol-Quer; Ernest Castro-Gutiérrez; Olivier Rosmorduc; Cyrille Feray; Emilio Ramos; Joan Figueras; Olivier Scatton; Daniel Azoulay
Journal:  World J Surg       Date:  2020-06       Impact factor: 3.352

Review 3.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

4.  Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤5 cm): A Propensity Score Matching Analysis.

Authors:  Han Wang; Hua Yu; You-Wen Qian; Zhen-Ying Cao; Meng-Chao Wu; Wen-Ming Cong
Journal:  Front Med (Lausanne)       Date:  2020-05-07

5.  Dose-Response Between Serum Prealbumin and All-Cause Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma.

Authors:  Rong-Rui Huo; Hao-Tian Liu; Zhu-Jian Deng; Xiu-Mei Liang; Wen-Feng Gong; Lu-Nan Qi; Xue-Mei You; Bang-De Xiang; Le-Qun Li; Liang Ma; Jian-Hong Zhong
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

6.  Prognostic Impact of Surgical Margin in Hepatectomy on Patients With Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies.

Authors:  Yeting Lin; Jiaxuan Xu; Jiaze Hong; Yuexiu Si; Yujing He; Jinhang Zhang
Journal:  Front Surg       Date:  2022-02-09

7.  Mitotic quiescence in hepatic cancer stem cells: An incognito mode.

Authors:  Kandasamy Ashokachakkaravarthy; Biju Pottakkat
Journal:  Oncol Rev       Date:  2020-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.